Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/AbbVie to buy Apogee Therapeutics for $10.9B, boosting its immunology and respiratory drug pipeline.
ABBV
$256.79
+$1.81 +0.71%

AbbVie to buy Apogee Therapeutics for $10.9B, boosting its immunology and respiratory drug pipeline.

Company Fundamentals
22 Jun 2026
Proactive Investors
View Source
Bullish
AbbVie to buy Apogee Therapeutics for $10.9B, boosting its immunology and respiratory drug pipeline.

AbbVie announced it will acquire Apogee Therapeutics in a $10.9 billion all-cash deal, gaining clinical-stage therapies for inflammatory and immunological diseases like atopic dermatitis and asthma. The acquisition includes Apogee's lead drug zumilokibart, showing promising Phase 2 results for skin clearance, and a combination therapy for asthma. The deal, approved by both companies' boards, is expected to close in Q3 2026 pending regulatory and shareholder approval. AbbVie expects the acquisition to strengthen its immunology portfolio and be accretive to earnings by 2032.

More News (ABBV)

AbbVie declares $1.73 quarterly dividend payable Nov 16 to shareholders of record Oct 15

AbbVie declares $1.73 quarterly dividend payable Nov 16 to shareholders of record Oct 15

AbbVie Inc. announced a quarterly cash dividend of $1.73 per share, payable on November 16, 2026, to shareholders recorded by October 15, 2026. Since its start in 2013, AbbVie has increased its dividend by over 330%, reflecting strong commitment to r...

Company Fundamentals
Bullish
16 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App